This issue of the OC Journal Hematology brings some discussions promoted during the American Society of Hematology (ASH) Annual Meeting, which took place at the end of 2020.
One of them is about REACH 3, a study whose data suggest a new therapeutic alternative for the second-line treatment of patients who, after transplantation, develop chronic graft-versus-host disease (GVHD). He compared the use of ruxolitinib (10 mg daily) with the best available treatment. Eduardo J. A. Paton, technical coordinator of Hematopoietic Cell Transplantation and Cell Therapy at Oncobio – MG and Biocor – MG, comments that ruxolitinib had a significantly higher overall response rate at the 24th week of treatment than BAT.
The TOURMALINE and APOLLO studies combine important data on the addition of ixazomib and daratumumab to other therapies to treat patients with multiple myeloma. Hematologist Rafael Cunha from the Oncological Treatment Center (CTO) of the Oncoclínicas Group in Rio de Janeiro, highlights that, in the TOURMALINE-MM2 study, “there was a clear benefit in progression-free survival, but without statistical significance. Patients who presented cytogenetic alterations with a poor prognosis were the ones who benefited the most from the association”. Hematologist Mariana Netto de Oliveira, physician at the Centro Paulista de Oncologia (CPO), from the Oncoclínicas Group, reports that, at APOLLO, the combination of daratumumab SC with the use of an immunomodulator (pomalidomide) did not increase the toxicity of the treatment: “There were only 6 % of infusion reaction, mainly in the first infusion, with the use of daratumumab SC, and 2% of reaction at the application site.”
Go to our website and read the full article with all the details of these studies.